Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

2.

Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers a Multi Institutional Study.

Rasmy A, Abozeed W, Elsamany S, Baiomy ME, Nashwa A, Amrallah A, Hasaan E, Alzahrani A, Faris M, Alsaleh K, AlFaraj A.

Asian Pac J Cancer Prev. 2016;17(7):3595-600.

3.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

4.

Drug therapies for metastatic castration-resistant prostate cancer.

El-Bahesh E, Finianos A, Alfaraj A, Aragon-Ching JB.

Future Oncol. 2015;11(17):2395-403. doi: 10.2217/fon.15.168. Epub 2015 Aug 14. Review.

PMID:
26274603

Supplemental Content

Loading ...
Support Center